Press release
Cyclin Dependent Kinase (CDK) Inhibitors Market Trends, Future Outlook, COVID-19 Impact Analysis, Forecast 2022-2028
The global cyclin dependent kinase (CDK) inhibitors market is anticipated to grow at a considerable CAGR during the forecast period. CDKs are nutrient metabolic enzymes that regulate the cell cycle. CDK binds to cyclin, forming a complex that works together. In the human body, there are approximately 20 members of the CDK family. Further, an inhibitor is any compound or chemical that inhibits the function of CDKs. Cancer cells proliferate excessively, and (CDK) inhibitors are used as a treatment to regulate this mechanism.A full report of Cyclin Dependent Kinase (CDK) Inhibitors Market is available at: https://www.omrglobal.com/industry-reports/cyclin-dependent-kinase-cdk-inhibitors-market
Some of the key factors driving the market growth of the CDK Inhibitors market include a rise in R&D spending and activities along with the increase in oncology research across the globe. The CDK inhibitor market is a highly opportunistic field for anticancer treatment due to the extensive use of CDK inhibitors in numerous clinical trials. For instance, in 2021, the University of Adelaide researchers discovered new evidence about the beneficial role of androgens in breast cancer treatment, which has immediate implications for women with estrogen receptor-driven metastatic disease.
Furthermore, in September 2021, Novartis Pharma AG Kisqali is the first CDK4/6 inhibitor to demonstrate a statistically significant life extension benefit in the front-line treatment of postmenopausal women with HR-positive, HER2-negative breast cancer. Kisqali has already won two clinical trials under its belt showing a survival benefit over traditional treatment. Now, the company released its third CDK inhibitor clinical trial, the first-of-its-kind victory in newly diagnosed patients that could give it a better shot at challenging Pfizer's market-leading Ibrance.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/cyclin-dependent-kinase-cdk-inhibitors-market
Market Coverage
• The market number available for - 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Type
o By Administration
o By Application
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- including Beta Pharma, Inc., Eli Lilly & Co., FLX Bio, Inc., G1 Therapeutics Inc., Novartis Pharma AG, and Pfizer Inc., among others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Cyclin Dependent Kinase (CDK) Inhibitors Market Report Segment
By Type
• Specific inhibitors
• Non-Specific or Broad Range Inhibitors
• Multiple target inhibitors
By Material
• Nasal
• Oral
• Intravenous
• Intramuscular
By Distribution Channel
• Breast cancer
• Lymphoma
• Multiple Myeloma
• Ovarian cancer
• Others (Cystic Fibrosis)
Cyclin Dependent Kinase (CDK) Inhibitors Market- Segment by Region
North America
• United States
• Canada
Europe
• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe
Asia-Pacific
• China
• Japan
• India
• Rest of Asia-Pacific
Rest of the World
• Middle East & Africa
• Latin America
Company Profiles
• Novartis Pharma AG
• Onconova Therapeutics, Inc.
• Pfizer Inc.
• Teijin Ltd.
• ViroStatics srl
• Xuanzhu Biopharmaceutical Co., Ltd.
Reasons to Buying From us -
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cyclin Dependent Kinase (CDK) Inhibitors Market Trends, Future Outlook, COVID-19 Impact Analysis, Forecast 2022-2028 here
News-ID: 2619586 • Views: …
More Releases from Orion Market Research
US Geriatric Medicine Market Size, Trends, Latest Insights, Analysis and Forecas …
The US geriatric medicine market is projected to grow at a CAGR of 4.6% during the forecast period. The US has high per capita income; access to advanced healthcare, a large elderly population, and a high prevalence of chronic diseases are some of the major factors driving the geriatric medicine market in the country.
Moreover, a significant presence of key market players, such as Pfizer Inc., Bristol-Myers Squibb Co., Abbott Laboratories…
Urometer Market Size, Trends, Latest Insights, Analysis and Forecast 2024-2031
The global urometer market is anticipated to grow at a considerable CAGR of 6.9% during the forecast period. The increasing cases of prostate cancer are expected to propel the growth of the global urometer market. Other than skin cancer, prostate cancer is the most common cancer in the US. According to the American Cancer Society (ACS), as of March 2022, around 268,490 new cases of prostate cancer and around…
Urethral Dilators Market Size, Trends, Latest Insights, Analysis and Forecast 20 …
The global urethral dilators market is anticipated to grow at a considerable CAGR of 4.9% during the forecast. The growing incidence of Healthcare-Acquired Infections (HAI) is Boosting the Global Urethral Dilators Market. These are infections that patients get while receiving treatment for medical or surgical conditions. These infections can be occurred in hospitals, surgical centers, ambulatory clinics, and long-term care facilities such as nursing homes and rehabilitation facilities.
To…
Transvaginal Endoscopy Market Will Exhibit an Impressive Expansion by 2024-2031
The global transvaginal endoscopy market is anticipated to grow at a significant CAGR of 7.3% during the forecast period. Some of the prominent factors driving the market growth during the forecast period include the rising incidence of infertility among the female rising incidence of infertility globally, coupled with the increasing use of minimally invasive surgery. The MIS procedures involves minminal use of surgical incisions, and with the advent of laproscopic…
More Releases for CDK
Investigation ongoing for Investors in CDK Global, Inc. (NASDAQ: CDK) over poten …
An investigation on behalf of investors in shares of CDK Global, Inc. (NASDAQ: CDK) was announced over potential breaches of fiduciary duties by certain officers and directors at CDK Global, Inc.
Investors who purchased shares of CDK Global, Inc. (NASDAQ: CDK) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain CDK Global, Inc. directors breached…
Cancer CDK Inhibitors Market 2021 | Detailed Report
According to Market Study Report, Cancer CDK Inhibitors Market provides a comprehensive analysis of the Cancer CDK Inhibitors Market segments, including their dynamics, size, growth, regulatory requirements, competitive landscape, and emerging opportunities of global industry. An exclusive data offered in this report is collected by research and industry experts team.
Get Free Sample PDF (including full TOC, Tables and Figures) of Cancer CDK Inhibitors Market @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5087783
The report provides a…
CDK Websites See Significant Organic Traffic Increases
REUNION MARKETING
Data Beats Intuition
418 S. Dawson St.
Raleigh, North Carolina 27601
NEWS RELEASE
For Immediate Release
CDK Websites See Significant Organic Traffic Increases
The Recent Google Algorithm Affected Traffic Flows Across CMSs
August 20, 2018 — Reunion Marketing personnel noted a remarkable increase in organic traffic for CDK websites that directly coincides with a Google algorithm update.
While conducting regular audits, members of the Reunion team discovered a pattern of significant increases in organic website traffic throughout…
Dealer Management Market Excellent Growth | IBM, CA, Cox Automotive, CDK Global
The qualitative research study conducted by HTF MI titled “Global Dealer Management Market Size, Status and Forecast 2025” provides primary Data, surveys, Scope of the Product and vendor briefings. The market dynamic forces have been determined after conducting a detailed study of the Global Dealer Managementmarket. The study provides forecasts for Dealer Management investments till 2022.
If you are involved in the Dealer Management industry or intend to be, then…
Global Cancer CDK Inhibitors Market and Clinical Pipeline Outlook 2022 Report
“Global Cancer CDK Inhibitors Market and Clinical Pipeline Outlook 2022” report highlights:
* Selectivity and Working Mechanism of a Cancer CDKs Inhibitor
* Recent Advances in the CDKs Related Cancer Therapy
* Global Cancer CDK Inhibitors Clinical Trials Insight: 45 Drugs in Pipeline
* Market Opportunity Assessment: More Than US$ 20 Billion (2022)
* Price Analysis of Cancer CDKs Inhibitors:
* Sales Analysis of Available Drugs: More Than US$ 2 Billion (2017)
Download Report Sample Weblink:…
Download Global Cancer CDK Inhibitors Market and Clinical Pipeline Outlook 2022
“Global Cancer CDK Inhibitors Market and Clinical Pipeline Outlook 2022” report gives comprehensive insight on clinical and non-clinical parameters related to emergence and growth of CDK inhibitors in cancer therapy. As per report findings, CDK inhibitors have emerged as new growth frontier for the organizations involved in the research, development, licensing and commercialization of targeted cancer therapies. There are 2 CDK inhibitors commercially available in the market for the treatment…
